## Annekathryn Goodman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5854316/publications.pdf

Version: 2024-02-01

115 papers 4,335 citations

117453 34 h-index 62 g-index

117 all docs

117 docs citations

117 times ranked

4197 citing authors

#	Article	IF	Citations
1	The challenges of screening large populations: transvaginal ultrasound and endometrial screening for endometrial cancer. Menopause, 2022, 29, 127-128.	0.8	O
2	Patient-reported outcomes and chemotherapy-related cognitive impairment in gynecologic malignancy. International Journal of Gynecological Cancer, 2022, 32, 781-787.	1.2	1
3	Deep-Learning–Based Evaluation of Dual Stain Cytology for Cervical Cancer Screening: A New Paradigm. Journal of the National Cancer Institute, 2021, 113, 1451-1452.	3.0	O
4	Patient reported outcome measures among patients with vulvar cancer at various stages of treatment, recurrence, and survivorship. Gynecologic Oncology, 2021, 160, 252-259.	0.6	10
5	Differential blood count as triage tool in evaluation of pelvic masses. International Journal of Gynecological Cancer, 2021, 31, 733-743.	1.2	4
6	Delay in diagnosis and increasing incidence of vulvar cancer: a root cause analysis. Menopause, 2021, 28, 111-112.	0.8	2
7	Total Antioxidant Capacity and Lipid Peroxidation Status in Cervical Cancer Patients Compared with Women Without Cervical Cancer in Bangladesh. Indian Journal of Gynecologic Oncology, 2021, 19, 1.	0.1	1
8	Is obesity predictive of endometrial cancer for women with postmenopausal bleeding?. Menopause, 2021, 28, 1081-1082.	0.8	3
9	Lymph node assessment at the time of hysterectomy has limited clinical utility for patients with pre-cancerous endometrial lesions. Gynecologic Oncology, 2021, 162, 613-618.	0.6	10
10	Cervical Cancer-Associated Suffering: Estimating the Palliative Care Needs of a Highly Vulnerable Population. JCO Global Oncology, 2021, 7, 862-872.	0.8	16
11	Essential Package of Palliative Care for Women With Cervical Cancer: Responding to the Suffering of a Highly Vulnerable Population. JCO Global Oncology, 2021, 7, 873-885.	0.8	15
12	Augmented Package of Palliative Care for Women With Cervical Cancer: Responding to Refractory Suffering. JCO Global Oncology, 2021, 7, 886-895.	0.8	6
13	Initial findings from a prospective, large scale patient reported outcomes program in patients with gynecologic malignancy. Gynecologic Oncology, 2021, , .	0.6	2
14	Prognostic Value of Preoperative Imaging. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 714-719.	0.6	4
15	Menopause and society: the association of educational level, social status, and financial status with positive versus negative perceptions about menopause. Menopause, 2020, 27, 630-631.	0.8	4
16	Factors associated with referral and completion of genetic counseling in women with epithelial ovarian cancer. International Journal of Gynecological Cancer, 2020, 30, 1397-1403.	1.2	4
17	Recognizing Moral Distress in the COVIDâ€19 Pandemic: Lessons From Global Disaster Response. Journal of Hospital Medicine, 2020, 15, 696-698.	0.7	16
18	Case 33-2019: A 35-Year-Old Woman with Cardiopulmonary Arrest during Cesarean Section. New England Journal of Medicine, 2019, 381, 1664-1673.	13.9	21

#	Article	IF	CITATIONS
19	Palliative Care Training for Work in an Austere Environment After a Natural Disaster. Prehospital and Disaster Medicine, 2019, 34, s54-s54.	0.7	О
20	Gender-Based Violence After A Natural Disaster. Prehospital and Disaster Medicine, 2019, 34, s133-s133.	0.7	1
21	Adjuvant Hysterectomy in Patients With Residual Disease After Radiation for Locally Advanced Cervical Cancer: A Prospective Longitudinal Study. Journal of Global Oncology, 2019, 5, 1-7.	0.5	12
22	Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?. Gynecologic Oncology, 2019, 153, 63-67.	0.6	17
23	Patterns of palliative care referral in ovarian cancer: A single institution 5†year retrospective analysis. Gynecologic Oncology, 2018, 148, 521-526.	0.6	35
24	Hematopoietic Stem-Cell Transplantation in the Resource-Limited Setting: Establishing the First Bone Marrow Transplantation Unit in Bangladesh. Journal of Global Oncology, 2018, 4, 1-10.	0.5	11
25	Endometrial cancer in the elderly: does patient age influence the choice of treatment interventions and do age-related treatment choices impact survival?. Menopause, 2018, 25, 963-964.	0.8	2
26	Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy. Obstetrics and Gynecology, 2017, 129, 861-869.	1.2	55
27	Risk-Reducing Strategies for Ovarian Cancer in <i>BRCA</i> Mutation Carriers: A Balancing Act. Oncologist, 2017, 22, 450-459.	1.9	36
28	Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology, 2017, 147, 250-256.	0.6	33
29	Management and outcome of cervical cancer diagnosed inÂpregnancy. American Journal of Obstetrics and Gynecology, 2017, 216, 276.e1-276.e6.	0.7	26
30	Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 177-178.	2.0	14
31	ETHICS in Disaster Response: The Development of an Ethics Disaster Response Program Prehospital and Disaster Medicine, 2017, 32, S50-S51.	0.7	1
32	Article Commentary: A Public Health Priority: Disparities in Gynecologic Cancer Research for African-Born Women in the United States. Clinical Medicine Insights Women's Health, 2016, 9, CMWH.S39867.	0.6	8
33	Mucinous Adenocarcinoma of the Endometrium Compared With Endometrioid Endometrial Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 43-48.	0.6	21
34	The Role of Lymphadenectomy Versus Sentinel Lymph Node Biopsy in Early-stage Endometrial Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 516-521.	0.6	22
35	Hematopoietic Stem Cell Transplantation in the Resource-Limited Setting: Establishing the First Bone Marrow Transplant Unit in Bangladesh and Initial Outcomes. Blood, 2016, 128, 2384-2384.	0.6	О
36	Medical Device Safety and Surgical Dissemination of Unrecognized Uterine Malignancy: Morcellation in Minimally Invasive Gynecologic Surgery. Oncologist, 2015, 20, 1274-1282.	1.9	16

#	Article	IF	CITATIONS
37	Changing Trends in Lymphadenectomy for Endometrioid Adenocarcinoma of the Endometrium. Obstetrics and Gynecology, 2015, 126, 815-822.	1.2	12
38	Teaching by Teleconference: A Model for Distance Medical Education across Two Continents. Open Journal of Obstetrics and Gynecology, 2015, 05, 754-761.	0.1	26
39	Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. Gynecologic Oncology, 2015, 137, 401-405.	0.6	51
40	The Mountains Are Angry. New England Journal of Medicine, 2015, 373, 203-205.	13.9	3
41	HPV testing as a screen for cervical cancer. BMJ, The, 2015, 350, h2372-h2372.	3.0	160
42	Surgical Apgar Score and prediction of morbidity in women undergoing hysterectomy for malignancy. Gynecologic Oncology, 2015, 136, 516-520.	0.6	35
43	Gynecologic Oncologist as surgical consultant: Intraoperative consultations during general gynecologic surgery as an important focus of gynecologic oncology training. Gynecologic Oncology, 2015, 137, 93-97.	0.6	15
44	Vitamin C and Cancer. AIMS Medical Science, 2015, 2, 41-51.	0.2	2
45	Teaching gynecologic oncology in Low resource settings: A collaboration of health volunteers overseas and the society of gynecologic oncology. Gynecologic Oncology, 2014, 135, 580-582.	0.6	13
46	Cervical Cancer Screening: The Complex Interplay of Medical Infrastructure, Society, and Culture. Oncologist, 2014, 19, 315-317.	1.9	8
47	Needs assessment of palliative care education in gynecologic oncology fellowship: We're not teaching what we think is most important. Gynecologic Oncology, 2014, 135, 255-260.	0.6	16
48	Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: A SEER analysis. Gynecologic Oncology, 2014, 133, 216-220.	0.6	125
49	Transitional cell carcinoma of the ovary: A case–control study. Gynecologic Oncology, 2014, 132, 649-653.	0.6	9
50	Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecologic Oncology, 2014, 132, 542-550.	0.6	128
51	Obstetrical care and women's health in the aftermath of disasters: The first 14 days after the 2010 Haitian earthquake. American Journal of Disaster Medicine, 2014, 9, 59-65.	0.1	11
52	Racial disparities in cervical cancer survival over time. Cancer, 2013, 119, 3644-3652.	2.0	55
53	Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement. Gynecologic Oncology, 2013, 129, 332-335.	0.6	39
54	Cervical Cancer Screening and Prevention in Low-resource Settings. Clinical Obstetrics and Gynecology, 2013, 56, 76-87.	0.6	60

#	Article	IF	Citations
55	The Role of Radical Surgery in the Management of Acquired Uterine Arteriovenous Malformation. Case Reports in Oncology, 2013, 6, 303-310.	0.3	10
56	Racial disparities in cervical cancer mortality over time Journal of Clinical Oncology, 2013, 31, 5604-5604.	0.8	О
57	Endometriosis-associated ovarian malignancy: a retrospective analysis of presentation, treatment, and outcome. Journal of reproductive medicine, The, 2013, 58, 469-76.	0.2	13
58	Acupuncture for Chemotherapy-Induced Nausea and Vomiting: A Retrospective Review of Patients' Experience at a Single Institution and a Review of the Literature. Medical Acupuncture, 2012, 24, 104-112.	0.3	2
59	The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial. Medical Acupuncture, 2012, 24, 233-240.	0.3	17
60	The Tensions and Challenges of Unpredictable Drug Shortages. American Journal of Bioethics, 2012, 12, 20-22.	0.5	4
61	Management of a skin metastasis in a patient with advanced ovarian cancer. Gynecologic Oncology Case Reports, 2012, 2, 124-126.	0.9	12
62	A snapshot of potentially personalized care: Molecular diagnostics in gynecologic cancer Journal of Clinical Oncology, 2012, 30, 5029-5029.	0.8	1
63	Hospital readmission after surgical cytoreduction for epithelial ovarian carcinoma: An assessment of risk Journal of Clinical Oncology, 2012, 30, e15545-e15545.	0.8	1
64	Primary debulking surgery (PDS) for stage IIIc ovarian cancer: <i>Quo vadis</i> ?. Journal of Clinical Oncology, 2012, 30, e15568-e15568.	0.8	0
65	The risk of squamous cell carcinoma in persistent vulvar ulcers. Menopause, 2011, 18, 1067-1071.	0.8	13
66	Prognostic Significance of Splenectomy as Part of Initial Cytoreductive Surgery in Ovarian Cancer. Annals of Surgical Oncology, 2011, 18, 2912-2918.	0.7	27
67	The Long-Term Effects of In Utero Exposures â€" The DES Story. New England Journal of Medicine, 2011, 364, 2083-2084.	13.9	40
68	Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecologic Oncology, 2010, 119, 462-468.	0.6	28
69	Double-Barreled Ileocolostomy Technique for the Treatment of Bowel Obstruction Secondary to Ovarian Cancer Recurrence. Journal of Gynecologic Surgery, 2010, 26, 283-287.	0.0	O
70	Case 8-2010. New England Journal of Medicine, 2010, 362, 1031-1040.	13.9	24
71	Ministry of Touch — Reflections on Disaster Work after the Haitian Earthquake. New England Journal of Medicine, 2010, 362, e37.	13.9	5
72	Acupuncture for Chemotherapy-Induced Neutropenia in Patients with Gynecologic Malignancies: A Pilot Randomized, Sham-Controlled Clinical Trial. Journal of Alternative and Complementary Medicine, 2009, 15, 745-753.	2.1	59

#	Article	IF	Citations
73	Case 10-2009. New England Journal of Medicine, 2009, 360, 1337-1344.	13.9	9
74	Abdominal radical trachelectomy: Success and pitfalls in a general gynecologic oncology practice. Gynecologic Oncology, 2009, 112, 506-510.	0.6	54
75	Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecologic Oncology, 2009, 114, 353-359.	0.6	108
76	Epithelioid angiosarcoma of the uterus: a review of management. Archives of Gynecology and Obstetrics, 2008, 278, 401-404.	0.8	36
77	Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecologic Oncology, 2008, 110, 293-298.	0.6	53
78	Granulocyte Colony-Stimulating Factor (G-CSF) Levels in a Randomized, Controlled Acupuncture Trial for Chemotherapy-Induced Neutropenia Blood, 2007, 110, 4088-4088.	0.6	0
79	A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk―endometrial cancer. Gynecologic Oncology, 2005, 96, 198-203.	0.6	37
80	Religious and cultural interpretation of illness in the Boston Haitian community and its impact on healthcare. Gynecologic Oncology, 2005, 99, S199-S200.	0.6	2
81	The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990–1999) at the Massachusetts General Hospital. Gynecologic Oncology, 2004, 92, 648-652.	0.6	157
82	Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecologic Oncology, 2004, 93, 98-106.	0.6	148
83	HPV Communication: Review of Existing Research and Recommendations for Patient Education. Ca-A Cancer Journal for Clinicians, 2004, 54, 248-259.	157.7	114
84	Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2004, 22, 2159-2166.	0.8	531
85	A case of Mýllerian adenosarcoma of the uterus treated with liposomal doxorubicin. Gynecologic Oncology, 2003, 88, 456-458.	0.6	17
86	Phase II trial of anastrozole in women with asymptomatic m $\tilde{A}^{1}/4$ llerian cancer. Gynecologic Oncology, 2003, 91, 596-602.	0.6	66
87	Case 32-2003. New England Journal of Medicine, 2003, 349, 1555-1564.	13.9	11
88	A Staff Dialogue on a Socially Distanced Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist, 2002, 7, 50-57.	1.9	1
89	A Staff Dialogue on a Socially Distanced Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist, 2002, 7, 50-57.	1.9	O
90	A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent mi;½llerian tumors. Cancer, 2001, 92, 1156-1167.	2.0	13

#	Article	IF	CITATIONS
91	The Clinical Utility of Liposomal Doxorubicin in Recurrent Ovarian Cancer. Gynecologic Oncology, 2001, 81, 206-212.	0.6	105
92	Anxiety and Uncertainty in Informed Decision Making. Journal of Women's Health and Gender-Based Medicine, 2001, 10, 93-94.	1.7	1
93	Role of routine human papillomavirus subtyping in cervical screening. Current Opinion in Obstetrics and Gynecology, 2000, 12, 11-14.	0.9	10
94	Intraoperative Radiation Therapy in the Treatment of Pelvic Gynecologic Malignancies: A Review of Fifteen Cases. Gynecologic Oncology, 2000, 79, 457-462.	0.6	21
95	The Role of Intraoperative Radiation Therapy (IORT) in the Treatment of Locally Advanced Gynecologic Malignancies. Oncologist, 2000, 5, 18-25.	1.9	27
96	Borderline tumors of the ovary: correlation of frozen and permanent histopathologic diagnosis. Obstetrics and Gynecology, 2000, 95, 839-843.	1.2	101
97	Quality of Life in Advanced Ovarian Cancer: Identifying Specific Concerns. Journal of Palliative Medicine, 1999, 2, 397-402.	0.6	26
98	Predictors of Recurrence in Surgical Stage II Endometrial Adenocarcinoma. Gynecologic Oncology, 1999, 73, 407-411.	0.6	37
99	Epithelial ovarian carcinoma in the reproductive age group. , 1999, 85, 2623-2629.		108
100	Stage IA1 Cervical Adenocarcinoma. Obstetrics and Gynecology, 1999, 93, 219-222.	1.2	20
101	Surveillance for Endometrial Cancer in Women Receiving Tamoxifen. Annals of Internal Medicine, 1999, 131, 127.	2.0	58
102	A Staff Dialogue on a Socially Distanced Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist, 1999, 4, 417-424.	1.9	1
103	Clinical Evaluation of Atypical Glandular Cells of Undetermined Significance on Cervical Cytology. Obstetrics and Gynecology, 1998, 91, 278-282.	1.2	95
104	The Power to Comfort. Journal of Palliative Medicine, 1998, 1, 291-291.	0.6	0
105	Stage IB and IIA Cervical Cancer with Negative Lymph Nodes: The Role of Adjuvant Radiotherapy after Radical Hysterectomy. Gynecologic Oncology, 1997, 66, 31-35.	0.6	76
106	Squamous Cell Carcinoma of the Endometrium: A Report of Eight Cases and a Review of the Literature. Gynecologic Oncology, 1996, 61, 54-60.	0.6	81
107	The Effect of Postsurgical Therapy on Stage III Endometrial Carcinoma. Gynecologic Oncology, 1996, 63, 34-39.	0.6	69
108	Prevalence of Prior Sexual Abuse and HIV Risk-taking Behaviors in Incarcerated Women in Massachusetts. Journal of Correctional Health Care, 1995, 2, 137-149.	0.2	5

#	Article	IF	CITATIONS
109	Uterine Papillary Serous Carcinoma (UPSC): A Clinicopathologic Study of 30 Cases. Gynecologic Oncology, 1995, 59, 384-389.	0.6	107
110	Surgical Stage IV Endometrial Carcinoma: A Study of 47 Cases. Gynecologic Oncology, 1994, 52, 237-240.	0.6	125
111	Molecular Genetic Changes Associated with Ovarian Cancer. Gynecologic Oncology, 1994, 55, 245-252.	0.6	34
112	Homogeneous Sampling Accounts for the Increased Diagnostic Accuracy Using the ThinPrep <sup>â,,¢</sup> Processor. American Journal of Clinical Pathology, 1994, 101, 215-219.	0.4	195
113	$M\tilde{A}^{1/4}$ llerian Inhibiting Substance as a Marker for Ovarian Sex-Cord Tumor. New England Journal of Medicine, 1992, 326, 466-471.	13.9	136
114	Preoperative serum CA-125 levels in borderline tumors of the ovary. Gynecologic Oncology, 1992, 46, 226-229.	0.6	39
115	Vaginal adenosis and clear cell carcinoma after 5-fluorouracil treatment for condylomas. Cancer, 1991, 68, 1628-1632.	2.0	46